Tenderwize
Back to tender search

Open-house pharmaceutical discount agreements for secukinumab

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 100 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Secukinumab, ATC L04AC10

54/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

54 / 100

Complexity

63 / 100

Risk factors

The notice provides no value, volume, minimum purchase, or guaranteed demand information, so the commercial return cann...

Open-house agreements may be replaced by exclusive rebate agreements and may then end automatically under the contractu...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Feb 28, 2027

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Conclusion of non-exclusive pharmaceutical rebate agreements under Sections 130a(8) and 130c(1) SGB V for medicines containing Secukinumab, ATC L04AC10.
  • Contract period from 2025-05-01 to 2027-04-30, with a maximum duration of 24 months for each agreement and an absolute end no later than 24 months after the earliest contract start.
Show full summary

Open-house pharmaceutical rebate agreement opportunity for Secukinumab (ATC L04AC10) in Germany, offered by AOK Rheinland-Pfalz/Saarland. The arrangement is non-exclusive, has no selection decision, uses uniform non-negotiable contractual conditions, and permits eligible pharmaceutical companies to join during the contract period. The notice states that this is not an award of a public contract under procurement law. No contract value is provided. The structured data indicates EU funding, while the XML notice states no EU funds; this inconsistency should be clarified.

Risks

The notice provides no value, volume, minimum purchase, or guaranteed demand information, so the commercial return cann...

Open-house agreements may be replaced by exclusive rebate agreements and may then end automatically under the contractu...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Only approved and marketable medicines in Germany may be supplied under the agreement.
  • If the medicine is listed as marketable in the Lauer-Taxe, this is accepted as evidence.

Administrative

  • If the medicine is not yet listed or the listing is not displayed, an extract from the public AMIce database must be submitted for the relevant medicines.

Buyer

Lots (1)

LOT-0001

Secukinumab Pharmaceutical Rebate Agreements

Non-exclusive open-house rebate agreements for medicines containing Secukinumab, ATC L04AC10. Agreements are available to all interested pharmaceutical companies meeting the stated medicinal-product requirements, without competitive selection or individual negotiations. Children’s medicines listed under the relevant BfArM list are excluded. Contracts may be concluded from the first day of each month during the maximum 24-month period and may be terminated subject to the contractual notice rules. Source data indicates that open-house agreements may end automatically if exclusive rebate agreements enter into force.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

Apr 2025 - Apr 2027

Category

Pharmaceutical products

Deadline

Deadline Feb 28, 2027

Procurement Details

Publication date
12 Mar 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
162068-2025

Documents (1)

Similar tenders

Cookies & Privacy

With your consent, we use Google Analytics, Microsoft Clarity (session recordings) and Google Ads cookies to understand how Tenderwize is used and to measure our advertising. You can change your choice at any time via “Cookie Settings” in the footer. Cookie Policy · Privacy Policy